Multiple Sclerosis Research Study

Researchers at The University of Michigan are interested in comparing the effects of CBD, THC, or both, on sleep and pain in persons with multiple sclerosis. Advance research today and join our compensated Clinical Trial!

Fast Facts

Diagnosed with Multiple Sclerosis

18-65 years old

Experience chronic pain

Compensation Provided

Conducted in Michigan

Study Background

The purpose of this research study is therefore to compare the effects of CBD, THC, or both, on sleep and pain in persons with MS.

The majority of people with Multiple Sclerosis (MS) experience problems with sleep, pain, or both.  Sleep problems affect more than half of people with MS.  Sleep problems also have the potential to worsen chronic pain, which affects about half of people with MS. Sleep problems and pain can be difficult symptoms to manage in MS.

Alternative treatments, such as CBD and/or THC (the chemical components in the cannabis plant, used in this study) are often used by people with MS to address their sleep problems, pain, or both. Although scientific evidence supporting the use of CBD and THC for sleep, pain, and other symptoms in MS is growing, little is known about how CBD and/or THC may help sleep, reduce pain, or perhaps even treat pain through better sleep.

Advance research today and join our compensated Clinical Trial!

Additional Information

The purpose of this research study is to compare the effects of CBD, THC, or both, on sleep and pain in persons with MS.

You may qualify for this study if you meet the following criteria:

Key Criteria:

  • Ages 18-65

  • Diagnosed with multiple sclerosis (MS)

  • Experience chronic pain

  • Willing to stay on stable treatment plan during study

  • If female, not pregnant, breastfeeding, or planning to become pregnant in the next six months

  • Willing to stop using any personal cannabis products during the 12 week study and within 30 days leading up to the study

  • No cardiovascular conditions including recent stroke, unstable angina, left ventricular hypertrophy, mitral valve prolapses, severe coronary artery disease, NYHA class III or IV congestive heart failure

Participation will occur over a span of 14 weeks and includes:

  • An initial 3 hr. in-person visit followed by up to three shorter visits up to 2 hrs.
  • Two overnight sleep studies
  • Blood draw (just over a teaspoon) at screening, mid-treatment, and final treatment visits
  • Two 14-day sessions wearing a wrist-worn sleep and activity sensor at home

 

You will be randomly assigned, by a computer program, to one of the 4 study drug groups:

  • Group 1: CBD (Epidiolex®, liquid)
  • Group 2: THC (Dronabinol capsules)
  • Group 3: THC (Dronabinol capsules) + CBD (Epidiolex)
  • Group 4: Placebo (inactive)

 

Before and at the end of the study, participants will wear a specialized wrist-worn monitor known as the PRO-DIARY for 14 days to measure symptoms, as well as sleep and physical activity.

Compensation is provided up to $400 for your time.

There is no cost for you to participate in the study.